By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Molecular diagnostics firm Biodesix said on Tuesday that it has received certification from the New York State Department of Health to offer its VeriStrat serum proteomic test.

As a result, the test, which is to help guide doctors in the treatment of patients with non-small cell lung cancer, is available in all 50 states. The test is performed in Biodesix's CLIA laboratory.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: map of human protein interactions, mutant phenotype variability in organisms of the same species from different genetic backgrounds, and more.

Critics call the Fred Hutchinson Cancer Research Center's Gary Gilliland's prediction of cancer cures within 10 years "out of touch with reality" and "irresponsible."

Ivan Oransky discusses the need for reproducibility research at The Conversation.

The San Diego Union-Tribune posts videos from Biocom's Speaker Series with Illumina's Jay Flatley, who discusses Roche's failed hostile takeover bid.